PTGX (Protagonist Therapeutics) Cash-to-Debt : 38.55 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Protagonist Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was 38.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Protagonist Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Protagonist Therapeutics's Cash-to-Debt or its related term are showing as below:

PTGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.82 Med: 182.16 Max: No Debt
Current: 38.55

During the past 11 years, Protagonist Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 7.82. And the median was 182.16.

PTGX's Cash-to-Debt is ranked better than
68.53% of 1481 companies
in the Biotechnology industry
Industry Median: 7.56 vs PTGX: 38.55

Protagonist Therapeutics Cash-to-Debt Historical Data

The historical data trend for Protagonist Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Protagonist Therapeutics Cash-to-Debt Chart

Protagonist Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

51.32

55.80

64.92

299.40

38.55

Protagonist Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															299.40	698.34	51.41	43.00	38.55

Competitive Comparison of Protagonist Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Protagonist Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagonist Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Protagonist Therapeutics's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Protagonist Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Protagonist Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	418.913	/	(0.51	+	10.356)
	=	38.55

Protagonist Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	418.913	/	(0.51	+	10.356)
	=	38.55

Protagonist Therapeutics (NAS:PTGX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Protagonist Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagonist Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website

https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Executives

William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Asif Ali	officer: Chief Financial Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D	director, officer: President and CEO	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta	officer: Chief Development Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd	director	3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick	director
Bryan Giraudo	director	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu	officer: Chief Scientific Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame	officer: Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035